Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

Abstract

The author of the above-mentioned paper would like to make the following adjustments to their article. In the Results section, under ‘Predefined Laboratory Abnormality Criteria’ and the subsection ‘Liver Enzymes’, the sentence in the first paragraph ‘‘...the proportion of patients whose last ALT measurement was C3 times the ULN were 0.8% and 0.6%, respectively [between-group difference 0.0]....’’, should state the ALT between-group difference as 0.2, rather than 0.0. In Table 3, the difference between Sitagliptin and Non-exposed (95% CI) for Neoplasms Benign, Malignant and Unspecified should read 0.5 (0.0, 1.0), rather than 0.6 (-0.0, 1.2). In Table 5, the lower bound for Dyspepsia should read 0.1, rather than 0.0. In Table 6 of the Appendix, the number of patients (N) is stated incorrectly in the second and third sections of the table. The N values in all sections should read: Sitagliptin group (N = 7,726) and Non-exposed group (N = 6,885). In Table 7 of the Appendix, the lower bound for Dyspepsia should read 0.1, not 0.0. Also, footnote ‘c’ should include ‘‘gastrointestinal pain’’. The authors thank Springer Healthcare for publishing the corrections.